MCID: CHR064
MIFTS: 43

Chronic Monocytic Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Chronic Monocytic Leukemia

MalaCards integrated aliases for Chronic Monocytic Leukemia:

Name: Chronic Monocytic Leukemia 12 15
Leukemia, Monocytic, Chronic 72
Leukemia, Myeloid 44

Classifications:



External Ids:

Disease Ontology 12 DOID:8593
ICD9CM 35 206.1
MeSH 44 D007951
NCIt 50 C34774
ICD10 33 C93.1
UMLS 72 C0023466

Summaries for Chronic Monocytic Leukemia

MalaCards based summary : Chronic Monocytic Leukemia, also known as leukemia, monocytic, chronic, is related to leukemia, acute myeloid and myeloid sarcoma. An important gene associated with Chronic Monocytic Leukemia is C3 (Complement C3), and among its related pathways/superpathways are Sertoli-Sertoli Cell Junction Dynamics and Focal Adhesion. The drugs Histamine and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Chronic Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Chronic Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 31.2 PTPRC MPO ITGAX ITGAM CD34
2 myeloid sarcoma 30.8 PTPRC MPO
3 precursor t-cell acute lymphoblastic leukemia 29.8 PTEN MPO CD34
4 essential thrombocythemia 29.8 MPO ITGAM F2
5 acute promyelocytic leukemia 28.3 PTPRC MPO ITGAX ITGAM CD34
6 atypical chronic myeloid leukemia 11.5
7 monocytic leukemia 10.5
8 leukemia 10.5
9 periodontosis 10.5 MPO ITGAM
10 granulocytopenia 10.4 MPO ITGAM
11 hypersensitivity vasculitis 10.4 MPO C3
12 endometrial small cell carcinoma 10.4 PTPRC F2
13 hypersensitivity reaction type iii disease 10.4 MPO C3
14 dendritic cell tumor 10.4 PTPRC MPO
15 chronic maxillary sinusitis 10.3 MPO C3
16 retina lymphoma 10.3 MPO CD34
17 extracutaneous mastocytoma 10.3 PTPRC CD34
18 lymphocytic leukemia 10.3
19 liver inflammatory pseudotumor 10.3 PTPRC CD34
20 glomeruloid hemangioma 10.3 PTPRC CD34
21 henoch-schoenlein purpura 10.3 MPO C3
22 conventional fibrosarcoma 10.2 PTPRC CD34
23 vulvar sarcoma 10.2 PTPRC CD34
24 ascending cholangitis 10.2 MPO F2 C3
25 hemangioma of liver 10.2 F2 CD34
26 aleukemic leukemia cutis 10.2 MPO CD34
27 leukemia, acute lymphoblastic 10.2
28 peritonitis 10.2 MPO ITGAM F2
29 sarcoma 10.2
30 spindle cell sarcoma 10.2
31 eccrine adenocarcinoma 10.2 F2 CD34
32 reticulohistiocytic granuloma 10.1 PTPRC CD34
33 proliferative glomerulonephritis 10.1 MPO C3
34 arteritic anterior ischemic optic neuropathy 10.1 MPO F2
35 lymphocytic vasculitis 10.0 ITGAX ITGAM
36 chronic myelomonocytic leukemia 10.0
37 acute leukemia 10.0
38 histiocytosis 10.0
39 malignant histiocytosis 10.0
40 splenomegaly 10.0
41 leukemia, chronic lymphocytic 10.0
42 myelodysplastic syndrome 10.0
43 leukemia, b-cell, chronic 10.0
44 gastrointestinal system cancer 9.9 PTEN F2 CD34
45 graft-versus-host disease 9.9
46 childhood acute lymphocytic leukemia 9.9
47 thrombocytopenia 9.9
48 myeloproliferative neoplasm 9.9
49 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.9
50 erythroleukemia, familial 9.8

Graphical network of the top 20 diseases related to Chronic Monocytic Leukemia:



Diseases related to Chronic Monocytic Leukemia

Symptoms & Phenotypes for Chronic Monocytic Leukemia

MGI Mouse Phenotypes related to Chronic Monocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 C3 CD34 EIF2AK1 F2 ITGAD ITGAM
2 homeostasis/metabolism MP:0005376 9.65 C3 CD34 EIF2AK1 F2 ITGAD ITGAM
3 immune system MP:0005387 9.32 C3 CD34 F2 ITGAD ITGAM ITGAX

Drugs & Therapeutics for Chronic Monocytic Leukemia

Drugs for Chronic Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 603)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
6
Lenalidomide Approved Phase 4 191732-72-6 216326
7
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
8
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
9
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
10
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
11 Molgramostim Investigational Phase 4 99283-10-0
12
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
13
Aclarubicin Investigational Phase 4 57576-44-0 451415
14
Histamine Phosphate Phase 4 51-74-1 65513
15 Cyclosporins Phase 4
16 Calciferol Phase 4
17 Bone Density Conservation Agents Phase 4
18 Vitamin D2 Phase 4
19 Ergocalciferols Phase 4
20 Hydroxycholecalciferols Phase 4
21 Angiogenesis Inhibitors Phase 4
22 Angiogenesis Modulating Agents Phase 4
23
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
24
Iron Approved, Experimental Phase 2, Phase 3 15438-31-0, 7439-89-6 23925 27284
25
Ondansetron Approved Phase 3 99614-02-5 4595
26
Fosaprepitant Approved Phase 3 172673-20-0 219090
27
Aprepitant Approved, Investigational Phase 3 170729-80-3 151165 6918365
28
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
29
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
30
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
31
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
32
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
33
Arsenic trioxide Approved, Investigational Phase 3 1327-53-3 518740
34
Mercaptopurine Approved Phase 3 50-44-2 667490
35
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
36
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
37
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
38
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
41
Pegaspargase Approved, Investigational Phase 3 130167-69-0
42
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
43
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
44
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
45
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
46
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
47
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
48
Enalaprilat Approved Phase 3 76420-72-9 6917719
49 Orange Approved Phase 2, Phase 3
50
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 2596)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
2 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
3 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
4 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
5 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
6 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
7 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
8 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy Unknown status NCT01243489 Phase 4
9 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
10 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
11 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
12 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
13 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
14 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
15 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
16 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
17 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
18 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
19 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
20 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
21 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
22 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
23 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
24 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
25 A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
26 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
27 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
28 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
29 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
30 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
31 An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
32 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
33 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
34 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
35 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
36 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
37 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
38 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415 Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
39 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
40 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Active, not recruiting NCT02875743 Phase 4 Posaconazole
41 A PHASE 4 SAFETY AND EFFICACY STUDY OF BOSUTINIB (BOSULIF (REGISTERED)) IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA PREVIOUSLY TREATED WITH ONE OR MORE TYROSINE KINASE INHIBITORS Active, not recruiting NCT02228382 Phase 4 Bosutinib
42 A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
43 A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID Active, not recruiting NCT02546674 Phase 4 Nilotinib
44 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
45 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Not yet recruiting NCT03988205 Phase 4 CPX-351
46 A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
47 PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5 Terminated NCT01198054 Phase 4 Lenalidomide
48 A Phase IV Study to Evaluate Efficacy and Safety of Imatinib(Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Terminated NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
49 Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib. Terminated NCT00461929 Phase 4
50 Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) Unknown status NCT01246752 Phase 3 Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)

Search NIH Clinical Center for Chronic Monocytic Leukemia

Cochrane evidence based reviews: leukemia, myeloid

Genetic Tests for Chronic Monocytic Leukemia

Anatomical Context for Chronic Monocytic Leukemia

MalaCards organs/tissues related to Chronic Monocytic Leukemia:

41
Myeloid, T Cells, Bone, Bone Marrow, Nk Cells, Monocytes, Testes

Publications for Chronic Monocytic Leukemia

Articles related to Chronic Monocytic Leukemia:

(show top 50) (show all 86)
# Title Authors PMID Year
1
Effect of Chronic Hematologic Malignancies on In-Hospital Outcomes of Patients With ST-Segment Elevation Myocardial Infarction. 38
31196560 2019
2
Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). 38
31263893 2019
3
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia. 38
29321428 2018
4
Air pollution from industrial waste gas emissions is associated with cancer incidences in Shanghai, China. 38
29484620 2018
5
Mandible exosomal ssc-mir-133b regulates tooth development in miniature swine via endogenous apoptosis. 38
30210900 2018
6
T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation. 38
28551327 2017
7
Risk for Health Care-Associated Bloodstream Infections in Pediatric Oncology Patients With Various Malignancies. 38
28038498 2017
8
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). 38
26834952 2016
9
A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. 38
26070419 2015
10
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. 38
26304895 2015
11
Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias. 38
25728710 2015
12
Extensive placental choriovascular infiltration by maturing myeloid cells in down syndrome-associated transient abnormal myelopoiesis. 38
25587735 2015
13
Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. 38
25619630 2015
14
Interpretation of personal genome sequencing data in terms of disease ranks based on mutual information. 38
26045178 2015
15
[Pulmonary function of children with acute leukemia in maintenance phase of chemotherapy]. 38
25510995 2014
16
A model approach to calculate cancer prevalence from 5 years survival data for selected cancer sites in India--part II. 38
25081685 2014
17
Proteome changes induced by c-myb silencing in human chronic myeloid leukemia cells suggest molecular mechanisms and putative biomarkers of hematopoietic malignancies. 38
24220303 2014
18
Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia. 38
23995854 2013
19
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. 38
23528871 2013
20
The emerging roles of Notch signaling in leukemia and stem cells. 38
24252593 2013
21
Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;). 38
23806379 2013
22
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome. 38
23049441 2012
23
Stem cell therapy in treatment of different diseases. 38
22359076 2012
24
Current views on the role of Notch signaling and the pathogenesis of human leukemia. 38
22128846 2011
25
Chemotherapeutic treatment for leukemia in a bearded dragon (Pogona vitticeps). 38
22946414 2011
26
BCR-ABL translocation in a dog with chronic monocytic leukemia. 38
21143615 2011
27
Identification of new markers discriminating between myeloid and lymphoid acute leukemia. 38
20670477 2010
28
Possible involvement of RasGRP4 in leukemogenesis. 38
19350351 2009
29
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. 38
16885047 2006
30
Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood. 38
16569592 2006
31
Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. 38
16357944 2006
32
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. 38
15837754 2005
33
Candidal prosthetic hip infection in a patient with previous candidal septic arthritis. 38
14973873 2004
34
A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia. 38
12792926 2003
35
Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. 38
12032870 2002
36
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. 38
11001891 2000
37
Dysregulation of lymphocyte proliferation by chromosomal translocations and sequential genetic changes. 38
10797481 2000
38
Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. 38
10468608 1999
39
Pediatric tumors in north west Pakistan and Afghan refugees. 38
9185211 1997
40
11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone. 38
8948668 1996
41
Biological characterization and molecular cloning of murine C-type retroviruses derived from the TSZ complex from mainland China. 38
7571406 1995
42
[Effect of media conditioned with bone marrow fibroblasts on proliferation of leukemic blast cell lines]. 38
7875517 1994
43
[The morphofunctional characteristics of the mononuclear phagocytes in the concentrated venous blood leukocytes of patients with histiocytosis]. 38
7985129 1994
44
Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis. 38
8412328 1993
45
Interleukin 1 augments the expression of the interleukin 2 receptor alpha-chain in interleukin 6-stimulated myeloid cells by a transcriptional and posttranscriptional mechanism. 38
1426100 1992
46
Inhibition of specific pathways of myeloid cell differentiation by an activated Hox-2.4 homeobox gene. 38
1359901 1992
47
A switch toward demethylation is associated with the expression of myeloperoxidase in acute myeloblastic and promyelocytic leukemias. 38
1327288 1992
48
[Effectiveness of etoposide on reactive histiocytosis and refractory state to platelet transfusion during therapy of leukemia: case report]. 38
1942543 1991
49
Down's syndrome and mixed acute leukemia in infants. 38
1829979 1991
50
[Agreement among observers in the classification of acute leukemias]. 38
1726336 1991

Variations for Chronic Monocytic Leukemia

Expression for Chronic Monocytic Leukemia

Search GEO for disease gene expression data for Chronic Monocytic Leukemia.

Pathways for Chronic Monocytic Leukemia

Pathways related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 PTEN ITGAX ITGAM ITGAD
2
Show member pathways
12.67 PTEN ITGAX ITGAM ITGAD
3
Show member pathways
12.63 PTEN ITGAX ITGAM ITGAD
4 12.34 ITGAX ITGAM ITGAD F2
5 12.27 PTPRC MPO LGALS1 CD34
6
Show member pathways
12 ITGAX ITGAM ITGAD F2
7 12 ITGAX ITGAM C3
8
Show member pathways
11.99 ITGAX ITGAM F2
9 11.92 MPO ITGAM C3
10
Show member pathways
11.92 ITGAX ITGAM ITGAD
11
Show member pathways
11.89 PTEN ITGAX ITGAM ITGAD
12 11.85 PTPRC ITGAM CD34
13
Show member pathways
11.8 ITGAX ITGAM C3
14 11.78 PTEN ITGAX ITGAM ITGAD
15 11.72 ITGAX ITGAM ITGAD
16 11.7 ITGAX ITGAM F2 C3
17 11.51 PTPRC ITGAM CD34
18 11.39 ITGAX ITGAM ITGAD C3
19 11.38 ITGAX ITGAM ITGAD
20 11.3 ITGAX ITGAM ITGAD
21 11.3 ITGAX ITGAM ITGAD
22 11.13 PTPRC ITGAX ITGAM CD34
23 11.09 PTPRC MPO ITGAX ITGAM CD34

GO Terms for Chronic Monocytic Leukemia

Cellular components related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.91 RGMB PTPRC PTEN ITGAX ITGAM ITGAD
2 external side of plasma membrane GO:0009897 9.55 PTPRC ITGAX ITGAM F2 CD34
3 membrane raft GO:0045121 9.5 RGMB PTPRC ITGAM
4 integrin complex GO:0008305 9.13 ITGAX ITGAM ITGAD
5 cell surface GO:0009986 9.1 PTPRC LGALS1 ITGAX ITGAM ITGAD CD34

Biological processes related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.65 LGALS1 F2 C3
2 cell adhesion GO:0007155 9.65 RGMB ITGAX ITGAM ITGAD CD34
3 extracellular matrix organization GO:0030198 9.63 ITGAX ITGAM ITGAD
4 leukocyte migration GO:0050900 9.61 ITGAX ITGAM CD34
5 neutrophil degranulation GO:0043312 9.55 PTPRC MPO ITGAX ITGAM C3
6 integrin-mediated signaling pathway GO:0007229 9.54 ITGAX ITGAM ITGAD
7 amyloid-beta clearance GO:0097242 9.4 ITGAM C3
8 positive regulation of phagocytosis, engulfment GO:0060100 9.02 C3
9 cell surface receptor signaling pathway involved in cell-cell signaling GO:1905114 8.96 ITGAM C3
10 heterotypic cell-cell adhesion GO:0034113 8.8 PTPRC ITGAX ITGAD

Molecular functions related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 8.8 PTPRC MPO F2

Sources for Chronic Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....